Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHEK Check-Cap	$0.68 -8.5%	$0.77	$0.56 ▼ $3.04	$4.33M	0.19	26,016 shs	49,114 shs
NDRA ENDRA Life Sciences	$4.84 -8.3%	$4.75	$2.90 ▼ $143.50	$3.97M	-0.18	4.98 million shs	26,967 shs
NUWE Nuwellis	$9.10 -5.2%	$15.36	$6.33 ▼ $175.98	$1.01M	N/A	2.33 million shs	177,054 shs
QNRX Quoin Pharmaceuticals	$6.66 -0.6%	$8.69	$5.01 ▼ $54.95	$3.94M	1.44	4,032 shs	3,184 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHEK Check-Cap	-6.59%	-9.71%	-10.89%	-14.82%	-66.31%
NDRA ENDRA Life Sciences	-8.33%	-26.67%	+34.44%	-21.17%	-99.93%
NUWE Nuwellis	-5.21%	-24.92%	-1.29%	-79.56%	-92.34%
QNRX Quoin Pharmaceuticals	-0.60%	-19.86%	-27.53%	+9.18%	-68.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHEK Check-Cap	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NDRA ENDRA Life Sciences	1.4186 of 5 stars	3.5	2.0	0.0	0.0	0.6	0.0	0.6
NUWE Nuwellis	1.9034 of 5 stars	3.5	2.0	0.0	0.0	1.1	0.0	1.3
QNRX Quoin Pharmaceuticals	1.7019 of 5 stars	0.0	5.0	0.0	0.0	2.4	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHEK Check-Cap	0.00	N/A	N/A	N/A
NDRA ENDRA Life Sciences	3.00	Buy	$50.00	933.06% Upside
NUWE Nuwellis	3.00	Buy	$714.00	7,746.15% Upside
QNRX Quoin Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NUWE, QNRX, NDRA, and CHEK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/13/2025	NUWE Nuwellis	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHEK Check-Cap	N/A	N/A	N/A	N/A	$4.05 per share	N/A
NDRA ENDRA Life Sciences	N/A	N/A	N/A	N/A	$4.77 per share	N/A
NUWE Nuwellis	$8.74M	0.10	N/A	N/A	$62.71 per share	0.15
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	$35.47 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHEK Check-Cap	-$17.57M	-$3.00	N/A	∞	N/A	N/A	N/A	N/A	N/A
NDRA ENDRA Life Sciences	-$11.51M	-$172.04	N/A	N/A	N/A	N/A	-140.96%	-106.14%	8/13/2025 (Estimated)
NUWE Nuwellis	-$11.16M	-$766.39	N/A	N/A	N/A	-112.09%	-655.31%	-141.83%	8/12/2025 (Estimated)
QNRX Quoin Pharmaceuticals	-$8.96M	-$48.81	N/A	N/A	N/A	N/A	-148.97%	-77.23%	8/7/2025 (Estimated)

Latest NUWE, QNRX, NDRA, and CHEK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	NDRA ENDRA Life Sciences	-$2.27	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	NUWE Nuwellis	-$0.45	N/A	N/A	N/A	$2.20 million	N/A
8/7/2025	Q2 2025	QNRX Quoin Pharmaceuticals	-$6.83	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	NUWE Nuwellis	-$18.90	-$28.98	-$10.08	-$0.69	$2.50 million	$1.90 million
5/13/2025	Q1 2025	QNRX Quoin Pharmaceuticals	-$3.85	-$6.50	-$2.65	-$6.50	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHEK Check-Cap	N/A	N/A	N/A	N/A	N/A
NDRA ENDRA Life Sciences	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHEK Check-Cap	N/A	N/A	N/A
NDRA ENDRA Life Sciences	N/A	3.85	3.85
NUWE Nuwellis	N/A	2.23	1.59
QNRX Quoin Pharmaceuticals	N/A	2.57	2.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHEK Check-Cap	1.07%
NDRA ENDRA Life Sciences	1.19%
NUWE Nuwellis	3.13%
QNRX Quoin Pharmaceuticals	8.63%

Insider Ownership

Company	Insider Ownership
CHEK Check-Cap	0.48%
NDRA ENDRA Life Sciences	0.04%
NUWE Nuwellis	1.60%
QNRX Quoin Pharmaceuticals	13.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHEK Check-Cap	80	5.85 million	5.82 million	Not Optionable
NDRA ENDRA Life Sciences	20	750,000	753,000	Not Optionable
NUWE Nuwellis	70	100,000	102,000	Not Optionable
QNRX Quoin Pharmaceuticals	4	590,000	509,000	Not Optionable

NUWE, QNRX, NDRA, and CHEK Headlines

Recent News About These Companies

Quoin Pharmaceuticals (QNRX) to Release Quarterly Earnings on Thursday

1 hour ago | americanbankingnews.com

Quoin Pharmaceuticals stock rises after positive clinical updates

July 31 at 3:14 AM | investing.com

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Product Portfolio Update

July 29, 2025 | finanznachrichten.de

Quoin Pharmaceuticals Provides Product Portfolio Update

July 29, 2025 | globenewswire.com

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases - Morningstar

June 27, 2025 | morningstar.comM

Quoin Pharmaceuticals Releases New Episode of NETHERTON NOW Featuring Expert Insights on Netherton Syndrome - Nasdaq

June 27, 2025 | nasdaq.com

QNRX - Quoin Pharmaceuticals Ltd ADR Executives - Morningstar

June 26, 2025 | morningstar.comM

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases

June 26, 2025 | finance.yahoo.com

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

June 24, 2025 | tmcnet.com

Quoin Pharmaceuticals, Ltd. (QNRX) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

QNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand Further

May 29, 2025 | finance.yahoo.com

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

May 22, 2025 | manilatimes.netM

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

May 20, 2025 | globenewswire.com

Quoin reports progress in pediatric skin disorder study

May 15, 2025 | investing.com

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

May 14, 2025 | globenewswire.com

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

May 14, 2025 | manilatimes.netM

A Peek at Quoin Pharmaceuticals's Future Earnings

May 12, 2025 | benzinga.com

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

May 1, 2025 | finanznachrichten.de

Quoin Pharmaceuticals regains Nasdaq compliance with bid price

May 1, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE, QNRX, NDRA, and CHEK Company Descriptions

Check-Cap NASDAQ:CHEK

$0.68 -0.06 (-8.47%)

Closing price 08/1/2025 03:58 PM Eastern

Extended Trading

$0.68 +0.00 (+0.71%)

As of 08/1/2025 07:18 PM Eastern

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

ENDRA Life Sciences NASDAQ:NDRA

$4.84 -0.44 (-8.33%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.84 0.00 (-0.10%)

As of 08/1/2025 07:51 PM Eastern

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Nuwellis NASDAQ:NUWE

$9.10 -0.50 (-5.21%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$9.09 -0.01 (-0.11%)

As of 08/1/2025 07:33 PM Eastern

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Quoin Pharmaceuticals NASDAQ:QNRX

$6.66 -0.04 (-0.60%)

Closing price 08/1/2025 03:56 PM Eastern

Extended Trading

$6.66 0.00 (0.00%)

As of 08/1/2025 04:10 PM Eastern

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time